These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Houot R; Kohrt HE; Marabelle A; Levy R Trends Immunol; 2011 Nov; 32(11):510-6. PubMed ID: 21907000 [TBL] [Abstract][Full Text] [Related]
24. Bevacizumab in colorectal cancer: current and future directions. Yeung Y; Tebbutt NC Expert Rev Anticancer Ther; 2012 Oct; 12(10):1263-73. PubMed ID: 23113577 [TBL] [Abstract][Full Text] [Related]
25. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis. Woodhouse CS; Morgan AC Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860 [TBL] [Abstract][Full Text] [Related]
26. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Noguchi T; Kato T; Wang L; Maeda Y; Ikeda H; Sato E; Knuth A; Gnjatic S; Ritter G; Sakaguchi S; Old LJ; Shiku H; Nishikawa H Cancer Res; 2012 Apr; 72(7):1672-82. PubMed ID: 22318866 [TBL] [Abstract][Full Text] [Related]
29. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. Michaud HA; Eliaou JF; Lafont V; Bonnefoy N; Gros L Oncoimmunology; 2014 Oct; 3(9):e955684. PubMed ID: 25941618 [TBL] [Abstract][Full Text] [Related]
30. Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma. Goldberg JL; Navid F; Hank JA; Erbe AK; Santana V; Gan J; de Bie F; Javaid AM; Hoefges A; Merdler M; Carmichael L; Kim K; Bishop MW; Meager MM; Gillies SD; Pandey JP; Sondel PM J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169872 [TBL] [Abstract][Full Text] [Related]
31. Antibody-based cancer therapy. Baxevanis CN Expert Opin Drug Discov; 2008 Apr; 3(4):441-52. PubMed ID: 23489099 [TBL] [Abstract][Full Text] [Related]
38. [Development of therapeutic antibodies for gastric and colorectal cancers]. Zhao TT; Fan NN; Lin L; Din Q; Zhan JB Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 May; 41(3):345-52. PubMed ID: 22723173 [TBL] [Abstract][Full Text] [Related]
39. A BRIEF SYNOPSIS OF MONOCLONAL ANTIBODY FOR THE TREATMENT OF VARIOUS GROUPS OF DISEASES. Puthenpurail A; Rathi H; Nauli SM; Ally A World J Pharm Pharm Sci; 2021 Nov; 10(11):14-22. PubMed ID: 35071113 [TBL] [Abstract][Full Text] [Related]
40. Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer. Arlen M; Arlen P; Coppa G; Crawford J; Wang X; Saric O; Dubeykovskiy A; Molmenti E World J Gastrointest Oncol; 2014 Jun; 6(6):170-6. PubMed ID: 24936227 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]